Head-to-head evidence
VH4004280 (VH-280) vs VH4527079
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV capsid · full HIV pipeline
VH4004280 (VH-280)
Developed by ViiV Healthcare
NCT06039579 · Phase 2 · completed
This is a randomized, double-blind, placebo-controlled parallel-group trial, but the primary endpoint is a surrogate biomarker (plasma HIV-1 RNA) rather than a hard clinical/endoscopic outcome, and the sample size is small (only 3-7 participants per arm), which limits precision and power. Although the posted results show large antiviral effects in the active arms relative to placebo, no statistical significance testing or confidence intervals are provided, so the primary comparison cannot be confirmed as met.
VH4527079
Developed by ViiV Healthcare
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: VH4004280 (VH-280)'s landscape · VH4527079's landscape